BridgeBio Pharma (BBIO) Short term Debt (2020 - 2026)

BridgeBio Pharma (BBIO) reported Short term Debt of $547.5 million for Q1 2026, up 14915.99% sequentially from $3.6 million in Q1 2021.

BridgeBio Pharma (BBIO) Short term Debt (2020 - 2026) Analysis & Trends

BridgeBio Pharma (BBIO) has 3 years of Short term Debt data on file, last reported at $547.5 million in Q1 2026.

For the quarter ending Q1 2026, Short term Debt changed N/A year-over-year to $547.5 million; the trailing twelve-month figure through Mar 2026 stood at $547.5 million (changed N/A YoY), and the FY2020 full-year result was $1.5 million, changed N/A from the prior year.
Short term Debt grew to $547.5 million in Q1 2026, from $3.6 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $547.5 million in Q1 2026 to a low of $547.5 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	BridgeBio Pharma	16.15 Bn	15.22 Bn	184.58 Mn

Download Data